Trials / Completed
CompletedNCT02500472
Investigation of Kava Effects on NNK Metabolism
Investigation of Kava Effects on the Metabolism of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Humans
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a non-therapeutic, single-arm pilot clinical trial in adult healthy smokers to assess whether kava can alter NNK metabolism in humans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Kava | 3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days. |
Timeline
- Start date
- 2015-12-03
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2015-07-16
- Last updated
- 2018-04-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02500472. Inclusion in this directory is not an endorsement.